株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

着床前検査の世界市場予測 2022年:着床前診断 (PGD) /着床前スクリーニング (PGS)、NGS、PCR、FISH、CGH、SNP

Preimplantation Genetic Testing Market by Type (Genetic Diagnosis/Genetic Screening), Technology (NGS, PCR, FISH, CGH, SNP), Products & Services, Application (Aneuploidy, Translocations), End User (Fertility Clinics, Research) - Forecast to 2022

発行 MarketsandMarkets 商品コード 529937
出版日 ページ情報 英文 207 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.53円で換算しております。
Back to Top
着床前検査の世界市場予測 2022年:着床前診断 (PGD) /着床前スクリーニング (PGS)、NGS、PCR、FISH、CGH、SNP Preimplantation Genetic Testing Market by Type (Genetic Diagnosis/Genetic Screening), Technology (NGS, PCR, FISH, CGH, SNP), Products & Services, Application (Aneuploidy, Translocations), End User (Fertility Clinics, Research) - Forecast to 2022
出版日: 2017年07月13日 ページ情報: 英文 207 Pages
概要

世界の着床前検査市場規模は、2017年の3億3,640万米ドルから、2022年までに5億4,180万米ドルへ、10.0%のCAGR (年間複合成長率) で拡大すると予測されています。世界的な不妊率の増加、着床前検査の領域における官民投資の増大、世界的な不妊治療院数の増加、遺伝子分析の領域における技術進歩、および母性年齢の上昇による胎児の染色体異常リスクの高さなどは、同市場の成長を促進する主要因となっています。

当レポートでは、世界の着床前検査市場について調査分析し、市場概要、産業動向、セグメント別の市場分析、競合情勢、主要企業などについて、体系的な情報を提供しています。

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

  • 着床前診断・スクリーニング:市場概要
  • 地域分析:着床前遺伝子診断・スクリーニング、技術別
  • 着床前診断・スクリーニング市場:アプリケーション別
  • 着床前診断・スクリーニング市場:製品・サービス別
  • 着床前診断・スクリーニング市場の地域概要

第5章 市場概要

  • イントロダクション
  • 市場発展:着床前診断・スクリーニング技術
  • 市場力学
    • 主な市場成長促進要因
    • 主な市場成長抑制要因
    • 主な市場機会
    • 主な市場課題

第6章 産業考察

  • バリューチェーン分析
  • ポーターのファイブフォース分析
  • 規制状況

第7章 着床前診断・スクリーニング市場:処置タイプ別

  • イントロダクション
  • 着床前スクリーニング (PGS)
  • 着床前診断 (PGD)

第8章 着床前診断・スクリーニング市場:技術別

  • イントロダクション
  • 次世代シーケンシング
  • ポリメラーゼ連鎖反応
  • 蛍光 in situ ハイブリダイゼーション
  • 比較ゲノムハイブリダイゼーション
  • 一塩基多型 (SNP)

第9章 着床前診断・スクリーニング市場:製品・サービス別

  • イントロダクション
  • 試薬・消耗品
  • 機器類
  • ソフトウェア・サービス

第10章 着床前診断・スクリーニング市場:アプリケーション別

  • 地域分析
  • イントロダクション
  • 異数性
  • 染色体構造異常
  • 単一遺伝子疾患
  • X連鎖遺伝病
  • HLAタイピング
  • 性別同定

第11章 着床前診断・スクリーニング市場:エンドユーザー別

  • イントロダクション
  • 助産院 & 不妊治療院
  • 病院、診断ラボおよびサービスプロバイダー
  • 研究ラボ & 大学機関

第12章 着床前診断・スクリーニング市場:地域別

  • イントロダクション
  • 北米
  • 欧州
  • アジア太平洋
  • その他

第13章 競合情勢

  • イントロダクション
  • 主要企業
  • 競合状況・動向
  • 世界の着床前遺伝子診断・スクリーニング市場における競合リーダーシップマッピング
  • 競合リーダーシップマッピング

第14章 企業プロファイル

  • 主な製品メーカー
    • ILLUMINA, INC.
    • THERMO FISHER SCIENTIFIC INC.
    • AGILENT TECHNOLOGIES, INC.
    • PERKINELMER, INC.
    • COOPERSURGICAL, INC. (THE COOPER COMPANIES, INC.子会社)
    • ABBOTT LABORATORIES
    • NATERA, INC. 166
    • RUBICON GENOMICS (TAKARA BIO USA HOLDINGS, INC.子会社)
    • OXFORD GENE TECHNOLOGY
    • YIKON GENOMICS
    • SCIGENE
  • 主なサービスプロバイダー
    • BEIJING GENOMICS INSTITUTE
    • GOOD START GENETICS, INC.
    • INVICTA GENETICS
    • COMBIMATRIX CORPORATION
    • GENEA LIMITED
    • PROGENESIS

第15章 付録

目次
Product Code: BT 5411

"Preimplantation genetic testing market projected to grow at a CAGR of 10.0%"

The global preimplantation genetic testing market is expected to reach USD 541.8 million by 2022 from USD 336.4 million in 2017, at a CAGR of 10.0%. Growing rate of infertility across the globe, increasing public-private investments in the field of preimplantation genetic testing, rising number of fertility clinics worldwide, technological advancements in the field of genetic analysis, and high risk of chromosomal abnormalities in the fetus with increasing maternal age are some of the key factors driving the growth of this market. However, the high procedural cost associated with preimplantation genetic testing and unsupportive government regulations are the factors restraining the growth of this market

"Next-generation Sequencing is expected to grow at the highest CAGR during 2017 to 2022"

By technology, the preimplantation genetic testing market covers next-generation sequencing (NGS), polymerase chain reaction (PCR), fluorescence in situ hybridization (FISH), comparative genomic hybridization (CGH), and single-nucleotide polymorphism (SNP). The NGS segment is expected to grow at the highest CAGR during 2017 to 2022, owing to benefits like reduced cost, better ability to detect an embryo with differing results (mosaicism), enhanced detection of structural abnormalities such as chromosomes with missing or duplicate segments, and reduction in human errors due to increased automation.

"The maternity centers & fertility clinics to dominate the global preimplantation genetic testing market during the forecast period"

On the basis of end users, the preimplantation genetic testing market is segmented into maternity centers & fertility clinics; hospitals, diagnostic labs, and service providers; and research laboratories & academic institutes. The maternity centers & fertility clinics segment accounted for the largest share of the global preimplantation genetic testing market in 2016 owing to the high success rate of treatments at fertility centers.

"APAC is projected to witness the highest growth during the forecast period "

While North America accounted for the largest share of the market in 2016, Asia-Pacific is expected to register the highest growth rate during the forecast period from 2017 to 2022. This is owing to the focus of key market players in this region, growing number of ART & IVF procedures in the region, continuous decline in average fertility rate, government initiatives for expansion and modernization of healthcare infrastructure across respective countries, and growing medical tourism across APAC countries.

Breakdown of supply-side primary interviews: by company type, designation, and region:

  • By Company Type - Tier 1 -50%, Tier 2 -33% and Tier 3 -17%
  • By Designation - C level - 17%, Director level - 50%, Others - 33%
  • By Region - North America - 34%, Europe - 26%, APAC - 35%, RoW - 5%

The major players in the market are Illumina, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), PerkinElmer, Inc. (U.S.), CooperSurgical, Inc. (U.S.), Beijing Genomics Institute (BGI) (China), Abbott Laboratories (U.S.), Natera, Inc. (U.S.), Genea Limited (Australia), Rubicon Genomics, Inc. (U.S.), and Oxford Gene Technology (U.K.), among others.

Research Coverage:

This report studies the preimplantation genetic testing market based on technology, product & service, procedure type, application, and end user. The report also analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting market growth. It evaluates opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micromarkets with respect to their growth trends, prospects, and contributions to the total market. The report forecasts the revenue of the market segments with respect to four main regions.

Reasons to Buy the Report:

This research focuses on various levels of analysis-industry trends, vendor dive analysis of 25 market players, and company profiles of top 15 market players-which together comprise and discuss basic views on the competitive landscape, emerging and high-growth segments of the preimplantation genetic testing market, and high-growth regions and countries and their respective drivers, restraints, challenges, and opportunities.

The report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on business strategies adopted by the major players in the preimplantation genetic testing market. The report analyzes the preimplantation genetic testing market based on technology, product & service, procedure type, application, end user, and region
  • Product Development/Innovation: Detailed insights on the upcoming technologies, research and development activities, and product launches in the preimplantation genetic testing market
  • Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various preimplantation genetic testing products across geographies
  • Market Diversification: Exhaustive information about new products and services, untapped geographies, recent developments, and investments in the preimplantation genetic testing market
  • Competitive Assessment: In-depth assessment of market shares, strategies, products and services, distribution networks, and manufacturing capabilities of leading players in the preimplantation genetic testing market

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. OBJECTIVES OF THE STUDY
  • 1.2. MARKET DEFINITION
  • 1.3. MARKETS COVERED
    • 1.3.1. YEARS CONSIDERED FOR THE STUDY
  • 1.4. CURRENCY USED
  • 1.5. LIMITATIONS
  • 1.6. STAKEHOLDERS

2. RESEARCH METHODOLOGY

  • 2.1. RESEARCH METHODOLOGY STEPS
    • 2.1.1. SECONDARY RESEARCH
      • 2.1.1.1. Key data from secondary sources
    • 2.1.2. PRIMARY RESEARCH
      • 2.1.2.1. Breakdown of primaries
      • 2.1.2.2. Key data from primary sources
  • 2.2. MARKET SIZE ESTIMATION
      • 2.2.1.1. Research methodology: bottom-up approach
      • 2.2.1.2. Research methodology: top-down approach
  • 2.3. RESEARCH DESIGN
  • 2.4. DATA VALIDATION AND TRIANGULATION
    • 2.4.1. ASSUMPTIONS FOR THE STUDY

3. EXECUTIVE SUMMARY

4. PREMIUM INSIGHTS

  • 4.1. PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING: MARKET OVERVIEW
  • 4.2. GEOGRAPHIC ANALYSIS: PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING MARKET, BY TECHNOLOGY (2016)
  • 4.3. PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING MARKET, BY APPLICATION, 2017. VS. 2022
  • 4.4. PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING MARKET, BY PRODUCT & SERVICE (2017. VS. 2022)
  • 4.5. GEOGRAPHICAL SNAPSHOT OF THE PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING MARKET

5. MARKET OVERVIEW

  • 5.1. INTRODUCTION
  • 5.2. MARKET EVOLUTION: PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING TECHNOLOGIES
  • 5.3. MARKET DYNAMICS
    • 5.3.1. MAJOR MARKET DRIVERS
      • 5.3.1.1. Declining fertility rates worldwide
      • 5.3.1.2. Increasing public-private investments in the field of preimplantation genetic testing
      • 5.3.1.3. Rising number of fertility clinics worldwide
      • 5.3.1.4. Technological advancements in the field of genetic analysis
      • 5.3.1.5. High risk of chromosomal abnormalities with advancing maternal age
    • 5.3.2. MAJOR MARKET RESTRAINTS
      • 5.3.2.1. High procedural cost associated with preimplantation genetic testing
      • 5.3.2.2. Unfavorable government regulations
    • 5.3.3. MAJOR MARKET OPPORTUNITIES
      • 5.3.3.1. Growth opportunities in emerging markets
        • 5.3.3.1.1. Improving healthcare infrastructure
        • 5.3.3.1.2. Growing medical tourism
        • 5.3.3.1.3. Growth initiatives by key market players
      • 5.3.3.2. Growing awareness on assisted reproduction techniques
    • 5.3.4. MAJOR MARKET CHALLENGES
      • 5.3.4.1. Socioethical concerns regarding preimplantation genetic testing
      • 5.3.4.2. Procedural limitations of preimplantation genetic testing with advancing age

6. INDUSTRY INSIGHTS

  • 6.1. VALUE CHAIN ANALYSIS
  • 6.2. PORTER'S FIVE FORCES ANALYSIS
  • 6.3. REGULATORY SCENARIO

7. PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING MARKET, BY PROCEDURE TYPE

  • 7.1. INTRODUCTION
  • 7.2. PREIMPLANTATION GENETIC SCREENING
  • 7.3. PREIMPLANTATION GENETIC DIAGNOSIS

8. PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING MARKET, BY TECHNOLOGY

  • 8.1. INTRODUCTION
  • 8.2. NEXT-GENERATION SEQUENCING
  • 8.3. POLYMERASE CHAIN REACTION
  • 8.4. FLUORESCENCE IN SITU HYBRIDIZATION
  • 8.5. COMPARATIVE GENOMIC HYBRIDIZATION
  • 8.6. SINGLE-NUCLEOTIDE POLYMORPHISM

9. PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING MARKET, BY PRODUCT AND SERVICE

  • 9.1. INTRODUCTION
  • 9.2. REAGENTS AND CONSUMABLES
  • 9.3. INSTRUMENTS
  • 9.4. SOFTWARE AND SERVICES

10. PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING MARKET, BY APPLICATION

  • 10.1. INTRODUCTION
  • 10.2. ANEUPLOIDY
  • 10.3. STRUCTURAL CHROMOSOMAL ABNORMALITIES
    • 10.3.1. TRANSLOCATIONS
    • 10.3.2. DELETIONS
    • 10.3.3. DUPLICATIONS
    • 10.3.4. INVERSIONS
  • 10.4. SINGLE GENE DISORDERS
  • 10.5. X-LINKED DISORDERS
  • 10.6. HLA TYPING
  • 10.7. GENDER IDENTIFICATION

11. PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING MARKET, BY END USER

  • 11.1. INTRODUCTION
  • 11.2. MATERNITY CENTERS & FERTILITY CLINICS
  • 11.3. HOSPITALS, DIAGNOSTIC LABS, AND SERVICE PROVIDERS
  • 11.4. RESEARCH LABORATORIES & ACADEMIC INSTITUTES

12. PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING MARKET, BY REGION

  • 12.1. INTRODUCTION
  • 12.2. NORTH AMERICA
    • 12.2.1. U.S.
    • 12.2.2. CANADA
  • 12.3. EUROPE
    • 12.3.1. GERMANY
    • 12.3.2. U.K.
    • 12.3.3. FRANCE
    • 12.3.4. REST OF EUROPE
  • 12.4. ASIA-PACIFIC
    • 12.4.1. CHINA
    • 12.4.2. JAPAN
    • 12.4.3. INDIA
    • 12.4.4. REST OF ASIA-PACIFIC
  • 12.5. REST OF THE WORLD

13. COMPETITIVE LANDSCAPE

  • 13.1. INTRODUCTION
  • 13.2. LEADING PLAYERS IN THE PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING MARKET
  • 13.3. COMPETITIVE SITUATION AND TRENDS
    • 13.3.1. AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS
    • 13.3.2. PRODUCT LAUNCHES AND APPROVALS
    • 13.3.3. ACQUISITIONS
    • 13.3.4. EXPANSIONS
    • 13.3.5. OTHER DEVELOPMENTS
  • 13.4. GLOBAL PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING COMPETITIVE LEADERSHIP MAPPING, 2017
    • 13.4.1. VISIONARY LEADERS
    • 13.4.2. INNOVATORS
    • 13.4.3. DYNAMIC DIFFERENTIATORS
    • 13.4.4. EMERGING COMPANIES
  • 13.5. COMPETITIVE LEADERSHIP MAPPING
    • 13.5.1. STRENGTH OF PRODUCT PORTFOLIO (FOR 25 PLAYERS)
    • 13.5.2. BUSINESS STRATEGY EXCELLENCE (FOR 25 PLAYERS)

Top 25 companies analysed for this study are - Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), Agilent Technologies, Inc. (U.S.), PerkinElmer, Inc. (U.S.), CooperSurgical, Inc. (U.S.), Abbott Laboratories (U.S.), Natera, Inc. (U.S.), Rubicon Genomics, Inc. (U.S.), Oxford Gene Technology (U.K.), Yikon Genomics (China), SciGene (U.S.), Beijing Genomics Institute (China), Good Start Genetics (U.S.), Invicta Genetics (Poland), CombiMatrix Corporation (U.S.), Genea Limited (Australia), Progenesis (U.S.), Arrayit Corporation (U.S.), Macrogen, Inc. (South Korea), Elucigene Diagnostics (U.K.), Reproductive Health Science Ltd. (Australia), Singlera Genomics, Inc. (U.S.), iGenomix (Spain), Source BioScience (U.K.), PacGenomics (U.S.)

14. COMPANY PROFILES (Overview, Products and Services, Financials, Strategy & Development)*

  • 14.1. TOP PRODUCT MANUFACTURERS
    • 14.1.1. ILLUMINA, INC.
    • 14.1.2. THERMO FISHER SCIENTIFIC INC.
    • 14.1.3. AGILENT TECHNOLOGIES, INC.
    • 14.1.4. PERKINELMER, INC.
    • 14.1.5. COOPERSURGICAL, INC. (A SUBSIDIARY OF THE COOPER COMPANIES, INC.)
    • 14.1.6. ABBOTT LABORATORIES
    • 14.1.7. NATERA, INC.
    • 14.1.8. RUBICON GENOMICS (A SUBSIDIARY OF TAKARA BIO USA HOLDINGS, INC.)
    • 14.1.9. OXFORD GENE TECHNOLOGY
    • 14.1.10. YIKON GENOMICS
    • 14.1.11. SCIGENE
  • 14.2. TOP SERVICE PROVIDER COMPANIES
    • 14.2.1. BEIJING GENOMICS INSTITUTE
    • 14.2.2. GOOD START GENETICS, INC.
    • 14.2.3. INVICTA GENETICS
    • 14.2.4. COMBIMATRIX CORPORATION
    • 14.2.5. GENEA LIMITED
    • 14.2.6. PROGENESIS

*Details on Overview, Products and Services, Financials, Strategy & Development might not be Captured in case of Unlisted Companies.

15. APPENDIX

  • 15.1. INSIGHTS OF INDUSTRY EXPERTS
  • 15.2. DISCUSSION GUIDE
  • 15.3. KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 15.4. INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
  • 15.5. AVAILABLE CUSTOMIZATIONS
  • 15.6. RELATED REPORTS
  • 15.7. AUTHOR DETAILS

LIST OF TABLES

  • TABLE 1: GLOBAL INCIDENCE RATE OF TRISOMY (2014)
  • TABLE 2: INCIDENCE RATE OF TRISOMY 21 IN THE U.S. (2014)
  • TABLE 3: PROCEDURAL COSTS FOR PGD & PGS TESTING ACROSS MAJOR COUNTRIES/REGIONS (2016)
  • TABLE 4: AVERAGE COST OF PGS-IVF PROCEDURES IN THE U.S. (2016)
  • TABLE 5: PUBLIC HEALTHCARE EXPENDITURE (% OF ANNUAL GDP): 2005 VS. 2014
  • TABLE 6: GLOBAL REGULATIONS GOVERNING PREIMPLANTATION GENETIC SCREENING AND DIAGNOSIS (2016)
  • TABLE 7: GLOBAL PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING MARKET SIZE, BY PROCEDURE TYPE, 2015-2022 (USD MILLION)
  • TABLE 8: PREIMPLANTATION GENETIC SCREENING MARKET SIZE, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 9: PREIMPLANTATION GENETIC DIAGNOSIS MARKET SIZE, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 10: GLOBAL PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING MARKET SIZE, BY TECHNOLOGY, 2015-2022 (USD MILLION)
  • TABLE 11: PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING MARKET SIZE FOR NGS, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 12: PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING MARKET SIZE FOR PCR, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 13: PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING MARKET SIZE FOR FISH, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 14: PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING MARKET SIZE FOR CGH, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 15: PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING MARKET SIZE FOR SNP, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 16: GLOBAL PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING MARKET SIZE, BY PRODUCTS & SERVICES, 2015-2022 (USD MILLION)
  • TABLE 17: PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING MARKET SIZE FOR REAGENTS AND CONSUMABLES, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 18: PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING MARKET SIZE FOR INSTRUMENTS, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 19: PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING MARKET SIZE FOR SOFTWARE AND SERVICES, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 20: GLOBAL PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING MARKET SIZE, BY APPLICATION, 2015-2022 (USD MILLION)
  • TABLE 21: ACCURACY OF PGS TECHNIQUES FOR ANEUPLOIDY
  • TABLE 22: PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING MARKET SIZE FOR ANEUPLOIDY, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 23: PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 24: GLOBAL PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 25: PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING MARKET SIZE FOR TRANSLOCATIONS, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 26: PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING MARKET SIZE FOR DELETIONS, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 27: PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING MARKET SIZE FOR DUPLICATIONS, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 28: PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING MARKET SIZE FOR INVERSIONS, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 29: PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING MARKET SIZE FOR SINGLE GENE DISORDERS, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 30: PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING MARKET SIZE FOR X-LINKED DISORDERS, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 31: PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING MARKET SIZE FOR HLA TYPING, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 32: PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING MARKET SIZE FOR GENDER IDENTIFICATION, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 33: GLOBAL PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING MARKET SIZE, BY END USER, 2015-2022 (USD MILLION)
  • TABLE 34: PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING MARKET SIZE FOR MATERNITY CENTERS & FERTILITY CLINICS, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 35: PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING MARKET SIZE FOR HOSPITALS, DIAGNOSTIC LABS, AND SERVICE PROVIDER COMPANIES, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 36: PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING MARKET SIZE FOR RESEARCH LABORATORIES & ACADEMIC INSTITUTES, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 37: PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING MARKET SIZE, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 38: NORTH AMERICA: MAJOR PGD AND PGS PRODUCT MANUFACTURERS AND SERVICE PROVIDER COMPANIES
  • TABLE 39: NORTH AMERICA: PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING MARKET SIZE, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 40: NORTH AMERICA: PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING MARKET SIZE, BY PROCEDURE TYPE, 2015-2022 (USD MILLION)
  • TABLE 41: NORTH AMERICA: PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING MARKET SIZE, BY TECHNOLOGY, 2015-2022 (USD MILLION)
  • TABLE 42: NORTH AMERICA: PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING MARKET SIZE, BY PRODUCT & SERVICE, 2015-2022 (USD MILLION)
  • TABLE 43: NORTH AMERICA: PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING MARKET SIZE, BY APPLICATION, 2015-2022 (USD MILLION)
  • TABLE 44: NORTH AMERICA: PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING MARKET SIZE FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 45: NORTH AMERICA: PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING MARKET SIZE, BY END USER, 2015-2022 (USD MILLION)
  • TABLE 46: REGULATIONS FOR INFERTILITY TREATMENT PROCEDURES IN THE U.S.
  • TABLE 47: U.S.: PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING MARKET SIZE, BY PROCEDURE TYPE, 2015-2022 (USD MILLION)
  • TABLE 48: CANADIAN LAWS ON INFERTILITY TREATMENT PROCEDURES (AS OF 2016)
  • TABLE 49: CANADA: PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING MARKET SIZE, BY PROCEDURE TYPE, 2015-2022 (USD MILLION)
  • TABLE 50: EUROPE: MAJOR PGD AND PGS PRODUCT MANUFACTURERS AND SERVICE PROVIDER COMPANIES
  • TABLE 51: EUROPE: PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING MARKET SIZE, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 52: EUROPE: PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING MARKET SIZE, BY PROCEDURE TYPE, 2015-2022 (USD MILLION)
  • TABLE 53: EUROPE: PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING MARKET SIZE, BY TECHNOLOGY, 2015-2022 (USD MILLION)
  • TABLE 54: EUROPE: PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING MARKET SIZE, BY PRODUCT & SERVICE, 2015-2022 (USD MILLION)
  • TABLE 55: EUROPE: PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING MARKET SIZE, BY APPLICATION, 2015-2022 (USD MILLION)
  • TABLE 56: EUROPE: PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING MARKET SIZE FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 57: EUROPE: PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING MARKET SIZE, BY END USER, 2015-2022 (USD MILLION)
  • TABLE 58: GERMANY: PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING MARKET SIZE, BY PROCEDURE TYPE, 2015-2022 (USD MILLION)
  • TABLE 59: U.K.: PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING MARKET SIZE, BY PROCEDURE TYPE, 2015-2022 (USD MILLION)
  • TABLE 60: FRANCE: PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING MARKET SIZE, BY PROCEDURE TYPE, 2015-2022 (USD MILLION)
  • TABLE 61: ROE: REGULATIONS FOR INFERTILITY TREATMENT (AS OF 2016)
  • TABLE 62: ROE: PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING MARKET SIZE, BY PROCEDURE TYPE, 2015-2022 (USD MILLION)
  • TABLE 63: ASIA-PACIFIC: MAJOR PGD AND PGS PRODUCT MANUFACTURERS AND SERVICE PROVIDER COMPANIES
  • TABLE 64: ASIA-PACIFIC: PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING MARKET SIZE, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 65: ASIA-PACIFIC: PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING MARKET SIZE, BY PROCEDURE TYPE, 2015-2022 (USD MILLION)
  • TABLE 66: ASIA-PACIFIC: PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING MARKET SIZE, BY TECHNOLOGY, 2015-2022 (USD MILLION)
  • TABLE 67: ASIA-PACIFIC: PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING MARKET SIZE, BY PRODUCT & SERVICE, 2015-2022 (USD MILLION)
  • TABLE 68: ASIA-PACIFIC: PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING MARKET SIZE, BY APPLICATION, 2015-2022 (USD MILLION)
  • TABLE 69: ASIA-PACIFIC: PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING MARKET SIZE FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 70: ASIA-PACIFIC: PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING MARKET SIZE, BY END USER, 2015-2022 (USD MILLION)
  • TABLE 71: CHINA: PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING MARKET SIZE, BY PROCEDURE TYPE, 2015-2022 (USD MILLION)
  • TABLE 72: JAPAN: PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING MARKET SIZE, BY PROCEDURE TYPE, 2015-2022 (USD MILLION)
  • TABLE 73: INDIA: PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING MARKET SIZE, BY PROCEDURE TYPE, 2015-2022 (USD MILLION)
  • TABLE 74: ROAPAC: PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING MARKET SIZE, BY PROCEDURE TYPE, 2015-2022 (USD MILLION)
  • TABLE 75: ROW: MAJOR PGD AND PGS PRODUCT MANUFACTURERS AND SERVICE PROVIDER COMPANIES
  • TABLE 76: ROW: PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING MARKET SIZE, BY PROCEDURE TYPE, 2015-2022 (USD MILLION)
  • TABLE 77: ROW: PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING MARKET SIZE, BY TECHNOLOGY, 2015-2022 (USD MILLION)
  • TABLE 78: ROW: PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING MARKET SIZE, BY PRODUCT & SERVICE, 2015-2022 (USD MILLION)
  • TABLE 79: ROW: PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING MARKET SIZE, BY APPLICATION, 2015-2022 (USD MILLION)
  • TABLE 80: ROW: PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING MARKET SIZE FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 81: ROW: PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING MARKET SIZE, BY END USER, 2015-2022 (USD MILLION)
  • TABLE 82: AGREEMENTS, COLLABORATIONS, PARTNERSHIPS, AND ALLIANCES 2014-2017
  • TABLE 83: PRODUCT LAUNCHES AND APPROVALS, 2014-2017
  • TABLE 84: ACQUISITIONS, 2014-2017
  • TABLE 85: OTHER DEVELOPMENTS, 2014-2017

LIST OF FIGURES

  • FIGURE 1: GLOBAL PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING MARKET: RESEARCH METHODOLOGY STEPS
  • FIGURE 2: BREAKDOWN OF SUPPLY-SIDE PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 3: DATA TRIANGULATION
  • FIGURE 4: GLOBAL PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING MARKET SIZE, BY TECHNOLOGY, 2017 VS. 2022 (USD MILLION)
  • FIGURE 5: GLOBAL PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING MARKET SHARE, BY PRODUCT & SERVICE, 2017 VS. 2022 (USD MILLION)
  • FIGURE 6: GLOBAL PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING MARKET SIZE, BY PROCEDURE TYPE, 2017 VS. 2022 (USD MILLION)
  • FIGURE 7: GLOBAL PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING MARKET SHARE, BY APPLICATION, 2017 VS. 2022 (USD MILLION)
  • FIGURE 8: GLOBAL PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING MARKET SHARE, BY END USER, 2017 VS. 2022 (USD MILLION)
  • FIGURE 9: GEOGRAPHICAL SNAPSHOT: PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING MARKET
  • FIGURE 10: DECLINING FERTILITY RATES & TECHNOLOGICAL ADVANCEMENTS IN THE FIELD OF GENETIC ANALYSIS ARE MAJOR FACTORS DRIVING MARKET GROWTH
  • FIGURE 11: NGS ACCOUNTED FOR THE LARGEST MARKET SHARE IN 2016
  • FIGURE 12: ANEUPLOIDY SEGMENT DOMINATES THE PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING MARKET
  • FIGURE 13: REAGENTS & CONSUMABLES SEGMENT WILL CONTINUE TO DOMINATE THE MARKET IN 2022
  • FIGURE 14: ASIA-PACIFIC TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD
  • FIGURE 15: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 16: GLOBAL FEMALE FERTILITY RATE (2004-2015)
  • FIGURE 17: U.S. GLOBAL HEALTH FUNDING: FAMILY PLANNING/REPRODUCTIVE HEALTH (2006-2016)
  • FIGURE 18: VALUE CHAIN ANALYSIS: PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING INDUSTRY (2016)
  • FIGURE 19: PORTER'S FIVE FORCES ANALYSIS: PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING MARKET (2016)
  • FIGURE 20: FEDERAL REGULATIONS IN THE U.S. ON GENETIC TESTING (2016)
  • FIGURE 21: PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING MARKET, BY PROCEDURE TYPE, 2017 VS. 2022 (USD MILLION)
  • FIGURE 22: PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING MARKET SIZE, BY TECHNOLOGY, 2017 VS. 2022 (USD MILLION)
  • FIGURE 23: PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING MARKET, BY PRODUCTS & SERVICES, 2017 VS. 2022 (USD MILLION)
  • FIGURE 24: PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING MARKET SIZE, BY APPLICATION, 2017 VS. 2022 (USD MILLION)
  • FIGURE 25: PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING MARKET SIZE, BY END USER, 2017 VS. 2022 (USD MILLION)
  • FIGURE 26: PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING MARKET, BY REGION
  • FIGURE 27: ASIA-PACIFIC TO GROW AT THE HIGHEST RATE DURING THE FORECAST PERIOD
  • FIGURE 28: NORTH AMERICA: PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING MARKET SNAPSHOT
  • FIGURE 29: EUROPE: PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING MARKET SNAPSHOT
  • FIGURE 30: ASIA-PACIFIC: PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING MARKET SNAPSHOT
  • FIGURE 31: ROW: PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING MARKET SNAPSHOT
  • FIGURE 32: GLOBAL PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING MARKET RANKING: TOP 5 PLAYERS (2016)
  • FIGURE 33: AGREEMENTS, PARTNERSHIPS, COLLABORATIONS, AND ALLIANCES-MAJORLY ADOPTED GROWTH STRATEGY BY MARKET PLAYERS FROM 2014 TO 2017
  • FIGURE 34: GLOBAL PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING COMPETITIVE LEADERSHIP MAPPING, 2017
  • FIGURE 35: ILLUMINA, INC.: COMPANY SNAPSHOT (2016)
  • FIGURE 36: THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2016)
  • FIGURE 37: AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2016)
  • FIGURE 38: PERKINELMER, INC.: COMPANY SNAPSHOT (2016)
  • FIGURE 39: THE COOPER COMPANIES INC.: COMPANY SNAPSHOT (2016)
  • FIGURE 40: ABBOTT LABORATORIES: COMPANY SNAPSHOT (2016)
  • FIGURE 41: NATERA, INC.: COMPANY SNAPSHOT (2016)
  • FIGURE 42: COMBIMATRIX CORPORATION: COMPANY SNAPSHOT (2016)
Back to Top